Notably, increased immune infiltration—typically considered favourable in other subtypes—was associated with poor outcomes in ER+/HER2‒ breast cancer, suggesting distinct immunological dynamics in this context.9, 10. The gene discussed is ERBB2; the disease is breast cancer.